Eli Lilly and Company

Indianapolis, Indiana

Classification

Public

About Financials People Deals Funding Keywords

About

Eli Lilly and Company is a global pharmaceutical corporation dedicated to discovering, developing, and delivering innovative medicines to improve people's lives around the world. With a legacy spanning over a century, the company remains committed to its core values of excellence, integrity, and respect for people. Eli Lilly focuses on therapeutic areas such as oncology, diabetes, immunology, neuroscience, and cardiovascular diseases, leveraging its expertise in research and development to address unmet medical needs and advance healthcare solutions. Product/Service Line Breakdown: 1. Oncology Therapeutics: Developing novel cancer treatments targeting various types of cancers. 2. Diabetes Care: Providing medications and solutions for the management of diabetes and related complications. 3. Immunology Products: Offering therapies for autoimmune diseases and related disorders. 4. Neuroscience Medications: Developing treatments for neurological conditions, including Alzheimer's disease and migraine. 5. Cardiovascular Pharmaceuticals: Producing medications for heart diseases and related conditions. 6. Animal Health Products: Providing a range of veterinary medicines and services that cater to the well-being of companion animals and livestock.

Financials

Revenue & Profit

Revenue

Profit (N/A)

Valuation

Ratios

Revenue / EBITDA

123 MM

Valuation / Revenue

123 MM

Valuation / Employees

$123 MM

EBITDA / Revenue

$123 MM

1-Year CAGR (Revenue)

3-Year CAGR (Revenue)

1-Year CAGR (Employees)

3-Year CAGR (Employees)

People

Employee Figures

Employees

Key Executives

Name	Title	Phone
John Doe	Employee	--
Jane Doe	Employee
John Doe	Employee
John Doe	Employee

401K

Total Active Participants

1234

No. Participants with Account Balances

56789

Total Liabilities Start of Year

1234

Total Assets Start of Year

56789

Deals

M&A2024-03-15Completed

Target

Acme Logistics Ltd

Buyer

Atlas Capital Partners

Seller

Founders Group

Investor Sponsors NorthBridge PE	Stake Tags 100%
Deal Amount $120M	Is PE deal Yes
Target Company Valuation $1.20 MM	Is deal PE backed Yes
Techniques Acquisition of Assets, Taken Private	Total Acquired 100%

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Buyer

Zenith Healthcare Group

Seller

Early Investors Consortium

Investor Sponsors --	Stake Tags Majority
Deal Amount Undisclosed	Is PE deal No
Target Company Valuation --	Is deal PE backed Yes
Techniques Secondary Sale, Management Buy-out (MBO)	Total Acquired 65%

Investor Sponsors

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

Is deal PE backed

Yes

Total Acquired

65%

Funding

Keywords

Classified

Private

No AI Training or Automated Data Extraction.

Use of this page or any content or data made available by PrivCo for scraping, crawling, indexing, caching, extracting, copying, reproducing, storing, or for training or developing any artificial intelligence or machine learning system is strictly prohibited without prior written consent. All access to and use of this page and PrivCo's services are subject to the PrivCo Terms of Use: https://www.privco.com/terms-of-use. No license or right is granted by implication or otherwise.